• Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS)
  • Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide
  • Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS)
  • The totality of RMS and PPMS data for fenebrutinib will be submitted to regulatory authorities